Related Articles
Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy
Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent
XELIRI compared with FOLFIRI as a second‑line treatment in patients with metastatic colorectal cancer
Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan‑induced toxicity in patients with cancer
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens